Page 1

EX - 99.1 2 d253417dex991.htm EX - 99.1 Exhibit 99.1 INTRA - CELLULAR THERAPIES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE CAPLYTA supplemental new drug applications ( sNDAs ) for the treatment of bipolar depression are under review by the FDA , with a PDUFA target action date of December 17 , 2021 . Bipolar depression launch preparations are progressing well ; sales force expansion is substantially complete . Total revenues were $ 22.2 million for the third quarter of 2021 , compared to $ 7.4 million for the same period in the prior year , representing an increase of approximately 200 % . CAPLYTA achieved net product revenues of $ 21.6 million for the third quarter of 2021. Third quarter CAPLYTA total prescriptions ( TRX ) increased 15 % versus the previous quarter . Patient enrollment is ongoing in a pivotal program evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder ( MDD ) . NEW YORK , November 9 , 2021 / GLOBE NEWSWIRE / — Intra - Cellular Therapies , Inc. ( Nasdaq : ITCI ) , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders , today announced its financial results for the third quarter ended September 30 , 2021 and provided a corporate update . " We are excited about the progress we have made during the third quarter in the commercialization of CAPLYTA in schizophrenia and in the advancement of our development programs . In addition , our bipolar depression launch preparations are progressing well and we have substantially completed our sales force expansion , " said Dr. Sharon Mates , Chairman and CEO of Intra - Cellular Therapies . Third Quarter Financial Highlights Total revenues were $ 22.2 million for the third quarter of 2021 , compared to $ 7.4 million of total revenues for the third quarter of 2020 . Net product revenues of CAPLYTA were $ 21.6 million for the third quarter of 2021 , compared to $ 7.4 million in net product revenues of CAPLYTA for the same period in 2020 .